Amycretin vs Semaglutide

How they differ

Each row below repeats what the two profiles cite. It is not a ranking or a recommendation.

Side by side

TopicAmycretinSemaglutide
What it is

An investigational single-molecule agonist of the GLP-1 and amylin receptors from Novo Nordisk. The 2026 Phase 2 report names it zenagamtide (formerly amycretin) and says it also acts on calcitonin receptors.1,2

A GLP-1 receptor agonist. The Wegovy label describes semaglutide as a GLP-1 analogue with 94% sequence similarity to human GLP-1.3

FDA status

In clinical trials

In clinical trials; not FDA-approved1,2

Not FDA-approved. The sources reviewed here describe it only in clinical trials sponsored by Novo Nordisk, including registered Phase 3 trials.1,2,7,8,9,10,11,12

Is amycretin FDA-approved?

FDA-approved

FDA-approved as Ozempic, Rybelsus and Wegovy3,4,5,6

FDA-approved. Drugs@FDA lists Ozempic (first approved December 5, 2017), Rybelsus (September 20, 2019) and Wegovy (June 4, 2021). The Wegovy label carries a boxed warning about thyroid C-cell tumors seen in rodents.3,4,5,6

Is semaglutide FDA-approved?

HHS compounding policy, October 30, 2026

Not among the six peptides the policy lists.13

Not among the six peptides the policy lists.13

FDA compounding safety-risk page

Not addressed in this profile’s sources.

Not addressed in this profile’s sources.

Kinds of studies cited

Smaller controlled human trials

  • Controlled human trial A first-in-human, double-blind, randomized, placebo-controlled Phase 1 trial in 144 adults with overweight or obesity, designed mainly to assess safety.14
  • Controlled human trial A randomized, placebo-controlled Phase 1b/2a trial in 125 adults with overweight or obesity at one research center, lasting up to 36 weeks.15
  • Controlled human trial A 36-week double-blind, randomized, placebo-controlled Phase 2 trial in which 262 adults with type 2 diabetes were randomized, published in The Lancet in 2026.2
  • Registered trial without results Six randomized Phase 3 trials of zenagamtide sponsored by Novo Nordisk and registered on ClinicalTrials.gov, none with posted results.7,8,9,10,11,12

Large randomized human trials

  • Large randomized human trial A double-blind, placebo-controlled cardiovascular trial (NCT03574597) that randomized 17,604 adults aged 45 or older with established cardiovascular disease and obesity or overweight, without diabetes. The label reports a hazard ratio of 0.80 for major adverse cardiovascular events.3
  • Large randomized human trial A 68-week randomized, double-blind, placebo-controlled weight trial (NCT03548935) in 1,961 adults with obesity, or overweight with a weight-related condition, that excluded type 2 diabetes. It is one of several weight trials the label describes.3
  • Large randomized human trial A randomized, double-blind, placebo-controlled MASH trial (NCT04822181) whose week-72 analysis included 800 adults with moderate to advanced liver fibrosis.3
Records collected

6 ClinicalTrials.gov records and 3 PubMed records collected

140 ClinicalTrials.gov records and 108 PubMed records collected

Area of study

Metabolic and weight1

Metabolic and weight, Heart and blood vessels, Liver3

Latest dated events
  1. ClinicalTrials.gov first posts AMBITION 1 and AMBITION 2, Phase 3 zenagamtide trials in type 2 diabetes.11,12
  2. ClinicalTrials.gov first posts AMAZE 13, the earliest-registered of the Phase 3 zenagamtide trials cited here.7
  3. Results of a Phase 2 trial in type 2 diabetes are published under the name zenagamtide.2
  1. FDA’s page on unapproved GLP-1 drugs is updated, as shown by its content-current date.16
  2. DailyMed publishes the Wegovy label version cited on this page.3
  3. FDA proposes excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list.17

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    Oral Amycretin in Japanese Men With Obesity · record history version 6 · last update posted 2025-03-05 ↗

    ClinicalTrials.gov · Official source · Source checked July 22, 2026

  2. 2
    Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial (2026) · PMID 42532080 ↗

    The Lancet · Official source · Source checked November 14, 2026

  3. 3
    WEGOVY (semaglutide) injection and tablet · SPL version 19 · published 2026-06-30 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked July 22, 2026

  4. 4
    Drugs@FDA application NDA209637 · original submission status AP · 2017-12-05 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  5. 5
    Drugs@FDA application NDA213051 · original submission status AP · 2019-09-20 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  6. 6
    Drugs@FDA application NDA215256 · original submission status AP · 2021-06-04 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  7. 7
    ClinicalTrials.gov record NCT07668401 · retained source version 2026-08-24:5833a93b62ac59e564069a1fd4bf8cd19222029a0b3f7ce99899f59f22b177dc ↗

    ClinicalTrials.gov · Official source · Source checked November 15, 2026

  8. 8
    ClinicalTrials.gov record NCT07720271 · retained source version 2026-09-28:93ed8b5caeb775d7d6fbd3c0d4e0c5ce26698ea8c1ae70efd4b447411785d74d ↗

    ClinicalTrials.gov · Official source · Source checked November 15, 2026

  9. 9
    ClinicalTrials.gov record NCT07797335 · retained source version 2026-09-01:bc9e4b3246b2a07cc90834c13fa40cb6e95033b38aa14b8b29396518aff35b74 ↗

    ClinicalTrials.gov · Official source · Source checked November 15, 2026

  10. 10
    ClinicalTrials.gov record NCT07861100 · retained source version 2026-10-06:c1032ee418d61646c75ff354e74a7285b9376c0eaeb82c0622036ec003177db0 ↗

    ClinicalTrials.gov · Official source · Source checked November 15, 2026

  11. 11
    ClinicalTrials.gov record NCT07931495 · retained source version 2026-11-12:23a664ffa2bff21e8dd34305b3456a3ee5f65f216d24ab4d40b786451213bde4 ↗

    ClinicalTrials.gov · Official source · Source checked November 15, 2026

  12. 12
    ClinicalTrials.gov record NCT07931547 · retained source version 2026-11-12:2d2f13db63aaf8b3fc36fdb710419bcd545343ee84a805e746017fc30430e350 ↗

    ClinicalTrials.gov · Official source · Source checked November 15, 2026

  13. 13
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  14. 14
    Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial (2025) · PMID 40550229 ↗

    The Lancet · Official source · Source checked November 14, 2026

  15. 15
    Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study (2025) · PMID 40550231 ↗

    The Lancet · Official source · Source checked November 14, 2026

  16. 16
    FDA’s concerns with unapproved GLP-1 drugs used for weight loss · content current as of October 1, 2026 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  17. 17
    FDA proposes to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list ↗

    U.S. Food and Drug Administration · Official source · Source checked July 29, 2026